Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 8, 2026, 4:58 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1609–1632 of 145,369 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Disorders Clear all

Conditions: Posttraumatic Stress Disorder, PTSD
Interventions: D-cycloserine, Placebo pill, CBT; Drug · Behavioral
Lead sponsor: Tulane University School of Medicine; Other
Eligibility: 13 Years to 18 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: New Orleans, Louisiana

Conditions: Major Depressive Disorder
Interventions: Iloperidone, Placebo; Drug
Lead sponsor: Maurizio Fava, MD; Other
Eligibility: 18 Years to 65 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Junctional Epidermolysis Bullosa, Dystrophic Epidermolysis Bullosa
Interventions: RGN-137, Placebo; Drug
Lead sponsor: Lenus Therapeutics, LLC; Industry
Eligibility: 4 Years and older
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 5
States / cities: Evanston, Illinois • Brooklyn, New York • Cincinnati, Ohio + 2 more

Conditions: Hearing Loss, Aging
Interventions: Clinic-based audiological rehabilitative service delivery, Telehealth audiological rehabilitative service delivery; Other
Lead sponsor: Johns Hopkins University; Other
Eligibility: 73 Years to 88 Years
Enrollment: 339 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 4
States / cities: Hagerstown, Maryland • Minneapolis, Minnesota • Jackson, Mississippi + 1 more

Conditions: Pruritus, Atopic Dermatitis
Interventions: Aurstat Anti-Itch Hydrogel (Aurstat); Drug
Lead sponsor: The Center for Clinical and Cosmetic Research; Other
Eligibility: 12 Years to 75 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013
U.S. locations: 1
States / cities: Aventura, Florida

Conditions: Hair Thinning
Interventions: Nutrafol Supplement Capsules, Placebo Capsules; Dietary Supplement · Other
Lead sponsor: Ablon Skin Institute Research Center; Other
Eligibility: 40 Years to 65 Years · Female only
Enrollment: 70 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Manhattan Beach, California

Conditions: Heart Disease
Interventions: Dexmedetomidine 1mcg/kg Intranasal, Dexmedetomidine 2mcg/kg Intranasal, Dexmedetomidine 1mcg Intravenous; Drug
Lead sponsor: Children's Hospital Medical Center, Cincinnati; Other
Eligibility: 6 Months to 48 Months
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Renal Impairment
Interventions: Emraclidine; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 58 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 5
States / cities: Tustin, California • Miami, Florida • Orlando, Florida + 1 more

Conditions: Cardiovascular Disease
Interventions: Cardiac MRI; Procedure
Lead sponsor: Cedars-Sinai Medical Center; Other
Eligibility: 18 Years to 85 Years · Female only
Enrollment: 433 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2051
U.S. locations: 2
States / cities: Los Angeles, California • Gainesville, Florida

Conditions: Cardiovascular Disease
Interventions: Strawberry Meal, Control Meal; Dietary Supplement
Lead sponsor: Penn State University; Other
Eligibility: 20 Years to 50 Years
Enrollment: 34 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: University Park, Pennsylvania

Conditions: Post Traumatic Stress Disorder
Interventions: Not listed
Lead sponsor: Central Arkansas Veterans Healthcare System; Federal
Eligibility: 18 Years to 60 Years
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 1
States / cities: North Little Rock, Arkansas

Conditions: Low Back Pain
Interventions: Embedded Emergency Department Physical Therapy, Usual Care; Other
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years and older
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 2
States / cities: Chicago, Illinois • Salt Lake City, Utah

Conditions: Colorectal Cancer
Interventions: Oral CC-486, Romidepsin, MK-3475; Drug
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years and older
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Lung Cancer
Interventions: gemcitabine hydrochloride, irinotecan hydrochloride; Drug
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years and older
Enrollment: 73 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2008
U.S. locations: 50
States / cities: Birmingham, Alabama • La Jolla, California • San Francisco, California + 31 more

Conditions: Reinforcing Value of Food
Interventions: Daily snack food intake; Behavioral
Lead sponsor: State University of New York at Buffalo; Other
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 53 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Diabetes, Gestational
Interventions: 1-Self-monitoring of blood glucose, 2-Self-weighing, 3-Self-checking of blood pressure, 4-Checking fetal heart rate, 5-Visits with caregivers; Device · Procedure
Lead sponsor: Kaiser Permanente; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Pasadena, California

Conditions: Multiple Sclerosis
Interventions: Teriflunomide, Placebo (for teriflunomide), Interferon-β [IFN-β], Glatiramer Acetate [GA]; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 182 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 1
States / cities: Bridgewater, New Jersey

Conditions: Alzheimer Disease, Early Onset
Interventions: 3TC; Drug
Lead sponsor: The University of Texas Health Science Center at San Antonio; Other
Eligibility: 50 Years to 80 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 3
States / cities: San Antonio, Texas

Conditions: Cystic Fibrosis, Methicillin-resistant Staphylococcus Aureus
Interventions: Vancomycin; Drug
Lead sponsor: Case Western Reserve University; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2021
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Influenza
Interventions: Trivalent inactivated influenza vaccine, Trivalent Baculovirus-expressed Influenza HA vaccine; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2005
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Respiratory Syncytial Virus Infections
Interventions: GSK3888550A RSV Maternal vaccine formulation 1, GSK3888550A RSV Maternal vaccine formulation 2, GSK3888550A RSV Maternal vaccine formulation 3, Placebo (Normal Saline); Biological · Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 502 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 2
States / cities: Lenexa, Kansas • Rochester, New York

Conditions: Chronic Plantar Fasciitis
Interventions: Corticosteroid injection (CSI) with local anesthetic (LA), Local anesthetic (LA) with Saline injection; Drug
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years and older
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Parkinson Disease
Interventions: Requip PR, Mirapex; Drug
Lead sponsor: Rajesh Pahwa, MD; Other
Eligibility: 18 Years and older
Enrollment: 61 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: Kansas City, Kansas

Conditions: Ulcerative Colitis
Interventions: Low Dose Budesonide, High Dose Budesonide, Placebo; Drug
Lead sponsor: Bausch Health Americas, Inc.; Industry
Eligibility: 5 Years to 17 Years
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 4
States / cities: Garden Grove, California • Indianapolis, Indiana • The Bronx, New York + 1 more

Search by objective public record fields.

D-cycloserine Adjunctive Treatment for Posttraumatic Stress Disorder (PTSD) in Adolescents

Iloperidone Augmentation of SSRIs for Patients With Major Depressive Disorder With Residual Anger and Irritability

Evaluation of the Safety and Efficacy Study of RGN-137 Topical Gel for Junctional and Dystrophic Epidermolysis Bullosa

ACHIEVE Hearing Intervention Follow-Up Study

Blinded, Randomized Study Evaluating Aurstat Versus Control in the Treatment of Atopic Dermatitis Associated Pruritus

Efficacy and Safety of a Nutraceutical Supplement With Standardized Botanicals in Peri-menopausal and Menopausal Women With Thinning Hair

Pharmacokinetic Study of Dexmedetomidine After Intra-nasal Dosing in Children

A Study to Evaluate Pharmacokinetic and Safety Trial of Emraclidine in Participants With Renal Impairment Compared With Participants With Normal Renal Function

Women's Ischemia Syndrome Evaluation (WISE) Coronary Vascular Dysfunction

Effect of Strawberries on Cardiovascular Disease Risk

Predicting Treatment Response Using Psychophysiologic Reactivity Measures

A Multi-Site Feasibility Trial of Embedded Emergency Department Physical Therapy

A Study of Enhancing Response to MK-3475 in Advanced Colorectal Cancer

Combination Chemotherapy in Treating Patients With Recurrent or Refractory Small Cell Lung Cancer

Food Reinforcement, Weight Status, and Energy Density

The Virtual Visit for Women With Gestational Diabetes

Long Term Safety of Teriflunomide When Added to Interferon-Beta or Glatiramer Acetate in Patients With Multiple Sclerosis

Pilot Study to Investigate the Safety and Feasibility of AntiRetroviral Therapy for Alzheimer's Disease

Pharmacokinetics of Vancomycin for Inhalation in Cystic Fibrosis

Trivalent Baculovirus-expressed Influenza HA Vaccine in Adults With Non-Hodgkin's B-cell Lymphoma

A Study to Evaluate Different Dose Levels of GlaxoSmithKline (GSK) Biologicals' Investigational Respiratory Syncytial Virus (RSV) Vaccine (GSK3888550A), Based on the Vaccine Safety and the Antibodies (Body Defences) Produced Following Vaccine Administration, When Given to Healthy Non-pregnant Women

Infracalcaneal Peppering Injection Technique for Chronic Plantar Fasciitis

Pramipexole Conversion to Ropinirole Controlled Release (CR)

Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Budesonide Extended-release Tablets in Pediatric Subjects Aged 5 to 17 Years With Active, Mild to Moderate Ulcerative Colitis